PRLD

Prelude Therapeutics Inc

Prelude Therapeutics Inc (PRLD) has 3 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Apr 28, 2026.

Insiders have net bought $25.0M over the trailing 6 months. The largest single insider purchase in this window was $12.5M by Director, 10% Owner ORBIMED ADVISORS LLC on Apr 21, 2026.

  • Industry:Biotechnology
  • CEO:Krishna Vaddi
  • Employees:79
  • HQ:Wilmington, DE, US
  • IPO:2020-09-25

Insider Buying

$25.0M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Unique Insiders

2

in the rolling window

Market Cap

$313.0M

Price slightly stale

Source
Purchase$12.5MApr 23SEC ↗
Bonita David PFirst filing
Purchase$12.5MApr 23SEC ↗

Related companies

Prelude Therapeutics Inc is in the Healthcare sector.